Skip to content

Creatine-Guanidinoacetic Acid Supplementation for Sarcopenia (CREGAAS)

The Effects of 6-month Supplementation With Creatine and Guanidinoacetic Acid on Biomarkers of Sarcopenia in Elderly

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04652921
Acronym
CREGAAS
Enrollment
30
Registered
2020-12-03
Start date
2020-09-15
Completion date
2021-12-31
Last updated
2022-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Brief summary

Sarcopenia-driven brain and muscle creatine deficit could be seen as a distinctive pathological facet of this condition, and this might be approached with targeted therapies in aim to restore creatine homeostasis in target tissues. Among potential therapeutic candidates, guanidinoacetate (GAA) appears recently as a direct precursor of creatine that may favorably upregulate muscle and brain creatine concentration. Interestingly, GAA-creatine mixture was found to be superior than creatine itself to effectively improves bioenergetics in the human brain and muscle in healthy humans, perhaps due to the unique transportability features of this combination. Here, we plan to evaluate does creatine-GAA supplementation affects various biomarkers of sarcopenia in elderly.

Interventions

DIETARY_SUPPLEMENTCreatine-guanidinoacetic acid

A dietary supplement provided as powder dissolved in a glass of water

OTHERInulin

A dietary supplement provided as powder dissolved in a glass of water

Sponsors

University of Novi Sad, Faculty of Sport and Physical Education
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
65 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Age \> 70 years * Free of acute disorders

Exclusion criteria

* History of dietary supplement use during the past 4 weeks

Design outcomes

Primary

MeasureTime frameDescription
Change in muscular strengthBaseline vs. 6 months post-interventionBaseline vs. 6 months

Secondary

MeasureTime frameDescription
Change in muscle massBaseline vs. 6 months post-interventionBaseline vs. 6 months
Change in muscle metabolites evaluated with MR spectroscopyBaseline vs. 6 months post-interventionBaseline vs. 6 months
Change in cognitive performance evaluated with Mini-Mental State Exam testBaseline vs. 6 months post-interventionBaseline vs. 6 months
Change in serum creatineBaseline vs. 6 months post-interventionBaseline vs. 6 months

Countries

Serbia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026